Literature DB >> 11966702

Treatment of disseminated granuloma annulare with a 5-lipoxygenase inhibitor and vitamin E.

Kathleen J Smith1, C Norwood, H Skelton.   

Abstract

Histologically, granuloma annulare (GA) is a common non-infectious necrobiotic granulomatous reaction pattern that correlates with a number of different, but relatively specific clinical presentations. The cause or causes of GA are unknown: when localized, it is usually self-limiting, but it may be persistent when disseminated. We present three women who had had disseminated GA for more than 1 year. One patient had previously been treated with isotretinoin with no response. All three patients were treated with vitamin E 400 IU daily and zileuton 2400 mg daily. All responded within 3 months with complete clinical clearing. The anti-inflammatory and immune regulatory effects of vitamin E and zileuton may be an effective treatment in some patients with prolonged disseminated/generalized GA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11966702     DOI: 10.1046/j.1365-2133.2002.04590.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Diverse manifestations associated with a single dermatosis.

Authors:  Jennifer Clay Cather; John Christian Cather
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-07

Review 2.  [Granuloma annulare].

Authors:  L Kowalzick
Journal:  Hautarzt       Date:  2005-11       Impact factor: 0.751

3.  rPbPga1 from Paracoccidioides brasiliensis Activates Mast Cells and Macrophages via NFkB.

Authors:  Clarissa Xavier Resende Valim; Elaine Zayas Marcelino da Silva; Mariana Aprigio Assis; Fabricio Freitas Fernandes; Paulo Sergio Rodrigues Coelho; Constance Oliver; Maria Célia Jamur
Journal:  PLoS Negl Trop Dis       Date:  2015-08-28

4.  Leukotriene Antagonists in Dermatology.

Authors:  Aditya Kumar Bubna
Journal:  Indian J Dermatol       Date:  2021 Sep-Oct       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.